Approves

Middlesex County approves policy change to increase awareness and integration of behavioral health – Insider NJ

by
Middlesex County approves policy change to increase awareness and integration of behavioral health - Insider NJ

Middlesex County Approves Policy Change to Increase Behavioral Health Awareness and Integration Rutgers Robert Wood Johnson Medical School, the Medical Society of NJ, the AMA and community leaders are at the forefront of integrating and delivering comprehensive behavioral health care. Middlesex County, New Jersey Middlesex County and its Department of… Continue Reading Middlesex County approves policy change to increase awareness and integration of behavioral health – Insider NJ

FDA Approves Eli Lilly’s Weight Loss Drug That Helped People Lose Up to 52 Pounds

by
FDA Approves Eli Lilly's Weight Loss Drug That Helped People Lose Up to 52 Pounds

The Food and Drug Administration on Wednesday has approved Zepbound, a new weight loss drug from drugmaker Eli Lilly that in clinical trials has been shown to help people lose up to 52 pounds in 16 months. Related to Zep is the latest entrant in the field of powerful new… Continue Reading FDA Approves Eli Lilly’s Weight Loss Drug That Helped People Lose Up to 52 Pounds

FDA approves Eli Lillys Zepbound, a weight loss drug similar to Ozempic and Wegovy

by
FDA approves Eli Lillys Zepbound, a weight loss drug similar to Ozempic and Wegovy

The Food and Drug Administration on Wednesday has approved Zepbound, a new weight loss drug from drugmaker Eli Lilly that in clinical trials has been shown to help people lose up to 52 pounds in 16 months. Related to Zep is the latest entrant in the field of powerful new… Continue Reading FDA approves Eli Lillys Zepbound, a weight loss drug similar to Ozempic and Wegovy

FDA approves renal denervation for high blood pressure

by
high blood pressure (hypertension) illustrated by female healthcare worker taking a male patient's blood pressure.png

American doctors finally have a new option for treating high blood pressure (hypertension) that remains insufficiently controlled despite medication and lifestyle changes. The FDA has approved Recor Medical’s Paradise Ultrasound Renal Denervation (RDN) System. The Palo Alto, Calif.-based company’s RDN system is designed to lower blood pressure by denervating the… Continue Reading FDA approves renal denervation for high blood pressure

FDA approves new treatment for erosive esophagitis

by
FDA approves new treatment for erosive esophagitis

The U.S. Food and Drug Administration (FDA) has approved vonoprazan tablets 10 mg and 20 mg (Voquezna, Phathom Pharmaceuticals) for the cure and maintenance of healing of all grades of erosive esophagitis, also known as erosive gastroesophageal reflux disease (GERD), as well as relief from associated heartburn, the company announced.… Continue Reading FDA approves new treatment for erosive esophagitis

FDA approves first Stelara biosimilar, Wezlana

by
FDA approves first Stelara biosimilar, Wezlana

Stelara is an interleukin-12 and interleukin-23 antagonist used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. The original product is available in intravenous and subcutaneous formulations. The FDA has approved Wezlana (ustekinumab-auub), making it the first approval for blockbuster biosimilar drug Stelara (ustekinumab). The agency… Continue Reading FDA approves first Stelara biosimilar, Wezlana

FDA approves Vonoprazan to treat erosive esophagitis

by
FDA approves Vonoprazan to treat erosive esophagitis

The U.S. Food and Drug Administration (FDA) approved Phathom Pharmaceuticals’ vonoprazan (Voquenza) on November 1, 2023 for the treatment of adults with erosive esophagitis (erosive GERD), a gastroesophageal reflux disease. The drug is expected to be commercially available by December 2023. The drug’s approval marks a critical moment for more… Continue Reading FDA approves Vonoprazan to treat erosive esophagitis

FDA approves secukinumab for adults with HS

by
FDA approves secukinumab for adults with HS

The U.S. Food and Drug Administration (FDA) has approved secukinumab for the treatment of adults with moderate to severe hidradenitis suppurativa (HS). This development, announced today, makes secukinumab the first and only interleukin (IL)-17A inhibitor approved by the FDA for the treatment of HS, which affects approximately 1% of the… Continue Reading FDA approves secukinumab for adults with HS

FDA Approves New Corticosteroid Treatment Option for DMD Patients | BioSpace

by
FDA Approves New Corticosteroid Treatment Option for DMD Patients | BioSpace

Pictured: A boy sitting in a wheelchair on a beach/iStock, ChiccoDodiFC The FDA on Thursday approved Santhera Pharmaceuticals’ new corticosteroid vamorolone, now marketed under the brand name Agamree, for the treatment of Duchenne muscular dystrophy. The announcement was made by Florida-based Catalyst Pharmaceuticals, which paid $90 million upfront in June… Continue Reading FDA Approves New Corticosteroid Treatment Option for DMD Patients | BioSpace

PHone : +14841287851

24 M Drive
East Hampton, NY 11937

© 2024 Copyright © Neurosciene - All rights reserved